Evidence map›Paper›PMID 42755356›Full record

ReviewJournal of enzyme inhibition and medicinal chemistry2026

Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential.

Mikołaj Biegański, Joanna Matysiak, Monika Szeliga

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mikołaj BiegańskiFaculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Joanna MatysiakDepartment of Chemistry, University of Life Sciences in Lublin, Lublin, Poland.
Monika SzeligaDepartment of Neurotoxicology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phthalazine derivatives are nitrogen-containing heterocyclic compounds that have gained considerable attention in medicinal chemistry due to their pharmacological potential. This review briefly outlines the biological properties and clinical application of five- and six-membered heterocycles. The main focus is placed on the recent advances in the development and biological evaluation of the phthalazine derivatives. A particular emphasis is put on their PARP and VEGFR inhibitory activity, which has been investigated in clinical trials for cancer treatment, ultimately leading to the market launch of some of these compounds. Furthermore, the recent studies on numerous phthalazine derivatives that demonstrate promising anticancer activity

Indexed as

Antineoplastic AgentsHeterocyclic CompoundsNeoplasmsPhthalazinesAnimalsCell ProliferationDrug Screening Assays, AntitumorHumansMolecular StructurePoly(ADP-ribose) PolymerasesReceptors, Vascular Endothelial Growth FactorStructure-Activity RelationshipAntineoplastic AgentsHeterocyclic CompoundsphthalazinePhthalazinesPoly(ADP-ribose) PolymerasesReceptors, Vascular Endothelial Growth Factorcancerclinical trialsdrug discoveryinhibitorPhthalazine derivative

Identifiers

PMID42755356
PMCPMC13591968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.